A novel optical imaging approach helps characterize the central nervous system phenotype of DM2 mice.
MDF holds an offsite planning meeting in January every year to look at the Care and Cure landscape for myotonic dystrophy. The annual goals are to identify urgent and high-impact opportunities to improve the quality of life of every person living with this disease while continuing to accelerate the search for therapies.
After a new review of the literature, the question of comorbidity of childhood DM1 and autism spectrum remains an open one.
Linda Marshall has written a moving overview of her struggles to find a diagnosis for the problems her children faced, and the particular impact of brain-related symptoms on her family.
Community member and MDF support group facilitator Mindy Kim responded to MDF’s call to advocates to contact their Congressional leadership last month, and her letter to the editor was published in the Greensboro News & Record.
MDF received fourteen applications from the U.S., Canada and Western Europe for the December fellowship proposal review, and is pleased to join with the Wyck Foundation to fund 4 new pre- and post-doctoral Fellows.
Expansion Therapeutics, a company founded on the basis of Dr. Matt Disney’s research, has received $55.3M in Series A financing to develop therapies for DM and other diseases.
MDF, in partnership with the Wyck Foundation and other donors, has announced $700,000 in funding to increase the number of sites in the Myotonic Dystrophy Clinical Research Network (DMCRN), and enable critically important new research.